<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412073</url>
  </required_header>
  <id_info>
    <org_study_id>582011</org_study_id>
    <nct_id>NCT01412073</nct_id>
  </id_info>
  <brief_title>Control of Blood Loss During Caesarean Section</brief_title>
  <official_title>A Randomized Trial to Determine the Best Strategy for the Control of Blood Loss at Elective Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      trial of 3 protocols to determine the best one to control blood loss during caesarean section
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will be divided into 3 groups each containing 200 women:

      Group (A): 200 patients will receive 5-IU oxytocin bolus over 3 minutes after delivery of the
      baby.

      Group (B): 200 patients will receive 5-IU oxytocin bolus over 3 minutes and 30-IU oxytocin
      infusion in 500 ml 0.9 % saline over 4 hours after delivery of the baby.

      Group (C): 200 patients will receive misoprostol 800 micrograms intrauterine, placed manually
      on the bottom of the uterine cavity after delivery of the placenta and cleaning of the
      cavity.

      Operative blood loss will be estimated in theatre based on the volume in the suction bottle
      and the weight of swabs used. We will record blood loss up until the time the woman will be
      discharged from the theatre recovery ward.

      Hemoglobin level and haematocrit value will be done as follow:-

        1. After admission of each case in the pre-operative period.

        2. Immediately post- operative.

        3. 24 hours post- operative.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount of blood loss</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin % and haematocrit value</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Complications; Cesarean Section</condition>
  <arm_group>
    <arm_group_label>oxytocin bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.
Hemoglobin level and haematocrit value will be done as follow:-
After admission of each case in the pre-operative period.
Immediately post- operative.
24 hours post- operative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin bolus &amp; oxytocin infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol intrauterine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours</description>
    <arm_group_label>oxytocin bolus</arm_group_label>
    <arm_group_label>oxytocin bolus &amp; oxytocin infusion</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby &amp; the placenta</description>
    <arm_group_label>misoprostol intrauterine</arm_group_label>
    <other_name>cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients booked for elective cesarean section.

          -  Singleton pregnancies.

          -  Primigravida or multipara ,first cesarean section or previous .

        Exclusion Criteria:

          -  Patients with obstetric hemorrhage.

          -  Uterine laceration.

          -  Placenta previa.

          -  Blood dyscrasias.

          -  Large fibroids.

          -  Multiple pregnancy.

          -  Pre-eclampsia.

          -  Marked maternal anemia.

          -  Previous history of PPH.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed M El-khayat, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of Obstetrics &amp; Gynecology , Faculty of medicine, Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>faculty of medicine , Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>12211</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>October 4, 2014</last_update_submitted>
  <last_update_submitted_qc>October 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Waleed El-khayat</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>caesarean section, intrapartum haemorrhage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

